Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.29 – $8.36
80% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $2.0M | $479.0K | $0 | $0 | $0 | $68.1M |
| Gross profit | $0 | $0 | −$2.0M | −$479.0K | $0 | $0 | $0 | −$68.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.6M | $3.8M | $13.3M | $42.8M | $61.5M | $93.8M | $70.7M | $17.5M |
| Operating income | −$5.0M | −$5.4M | −$20.0M | −$64.0M | −$104.0M | −$125.5M | −$100.9M | −$102.3M |
| EBITDA | −$79.0K | −$4.8M | −$19.6M | −$54.4M | −$88.0M | −$126.0M | −$95.8M | $643.0K |
| Net income | −$5.1M | −$5.2M | −$20.0M | −$54.9M | −$95.6M | −$117.7M | −$96.9M | −$105.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.60 | -1.40 | -6.10 | -14.90 | -25.30 | -30.90 | -25.20 | -24.70 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-4.87 | $-5.03–$-4.71 | 2 |
| 2027 | $0 | $-0.40 | $-0.40–$-0.40 | 1 |
| 2028 | $0 | $-0.43 | $-0.43–$-0.43 | 1 |
| 2029 | $0 | $-0.45 | $-0.45–$-0.45 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ATHA.
No tracked institution reports a position in ATHA as of their last filing.
No one on the platform has traded ATHA yet.
| $6M |
| — |
| DAREDare Bioscience, Inc. | $2.10 | +0.48% | $20M | — |
| FBLGFibroBiologics, Inc. Common Stock | $0.79 | -3.78% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.